The DOI matches its Crossref record; 33 of the 33 references it cites were found in a registry or an index.
Results at Recruitment From a Randomized Controlled Trial Comparing Human Papillomavirus Testing Alone With Conventional Cytology as the Primary Cervical Cancer Screening Test
Abstract
BACKGROUND: In the first recruitment phase of a randomized trial of cervical cancer screening methods (New Technologies for Cervical Cancer Screening [NTCC] study), we compared screening with conventional cytology with screening by human papillomavirus (HPV) testing in combination with liquid-based cytology. HPV-positive women were directly referred to colposcopy if aged 35 or older; if younger, they were retested after 1 year. METHODS: In the second recruitment phase of NTCC, we randomly assigned women to conventional cytology (n = 24,661) with referral to colposcopy if cytology indicated atypical squamous cells of undetermined significance or more severe abnormality or to testing for high-risk HPV DNA alone by Hybrid Capture 2 (n = 24,535) with referral to colposcopy if the test was positive at a concentration of HPV DNA 1 pg/mL or greater. For the main endpoint of the study, histologic detection of cervical intraepithelial neoplasia of grade 2 or more (CIN2+), we calculated and compared sensitivity and positive predictive value (PPV) of the two screening methods using HPV DNA cutoffs of 1 pg/mL and 2 pg/mL. All statistical tests were two-sided. RESULTS: For women aged 35-60 years, the relative sensitivity of HPV testing for detection of CIN2+ at a cutoff of 1 pg/mL vs conventional cytology was 1.92 (95% CI = 1.28 to 2.87) and the relative PPV was 0.80 (95% CI = 0.55 to 1.18). At a cutoff of 2 pg/mL HPV DNA, the relative sensitivity was 1.81 (95% CI = 1.20 to 2.72) and the relative PPV was 0.99 (95% CI = 0.67 to 1.46). In this age group, there was no evidence of heterogeneity between study phases. Among women aged 25-34 years, the relative sensitivity for detection of CIN2+ of HPV testing at a cutoff of 1 pg/mL vs cytology was 3.50 (95% CI = 2.11 to 5.82), statistically significantly larger (P = .019) than that observed in phase 1 at this age (1.58; 95% CI = 1.03 to 2.44). CONCLUSIONS: For women aged 35-60 years, HPV testing with a cutoff of 2 pg/mL achieves a substantial gain in sensitivity over cytology with only a small reduction in PPV. Among women aged 25-34 years, the large relative sensitivity of HPV testing compared with conventional cytology and the difference between relative sensitivity during phases 1 and 2 suggests that there is frequent regression of CIN2+ that are detected by direct referral of younger HPV-positive women to colposcopy. Thus, triage test or repeat testing is needed if HPV is to be used for primary testing in this context.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Statistical Methods in Cancer Research
Breslow, N. E. (1980) · Cited by 7,332
Statistical methods in cancer research. Volume I - The analysis of case-control studies.
Breslow, N. E., & Day, N. E. (1980) · PubMed · Cited by 4,988
Harper, D. M., Franco, E. L., Wheeler, C. M., Moscicki, A.-B., Romanowski, B., Roteli-Martins, C. M., Jenkins, D., Schuind, A., Costa Clemens, S. A., & Dubin, G. (2006) · The Lancet · doi:10.1016/s0140-6736(06)68439-0 · Cited by 1,632
Cuzick, J., Clavel, C., Petry, K., Meijer, C. J. L. M., Hoyer, H., Ratnam, S., Szarewski, A., Birembaut, P., Kulasingam, S., Sasieni, P., et al. (2006) · International Journal of Cancer · doi:10.1002/ijc.21955 · Cited by 1,141
Self-citationKyrgiou, M., Koliopoulos, G., Martin-Hirsch, P., Arbyn, M., Prendiville, W., & Paraskevaidis, E. (2006) · The Lancet · doi:10.1016/s0140-6736(06)68181-6 · Cited by 1,120
Human Papillomavirus DNA versus Papanicolaou Screening Tests for Cervical Cancer
Mayrand, M.-H., Duarte-Franco, E., Rodrigues, I., Walter, S. D., Hanley, J., Ferenczy, A., Ratnam, S., Coutlée, F., & Franco, E. L. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa071430 · Cited by 1,100
Woodman, C. B., Collins, S., Winter, H., Bailey, A., Ellis, J., Prior, P., Yates, M., Rollason, T. P., & Young, L. S. (2001) · The Lancet · doi:10.1016/s0140-6736(00)04956-4 · Cited by 822
Human Papillomavirus and Papanicolaou Tests to Screen for Cervical Cancer
Naucler, P., Ryd, W., Törnberg, S., Strand, A., Wadell, G., Elfgren, K., Rådberg, T., Strander, B., Johansson, B., Forslund, O., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa073204 · Cited by 797
Bulkmans, N., Berkhof, J., Rozendaal, L., van Kemenade, F., Boeke, A., Bulk, S., Voorhorst, F., Verheijen, R., van Groningen, K., Boon, M., et al. (2007) · The Lancet · doi:10.1016/s0140-6736(07)61450-0 · Cited by 637
Schiffman, M., Herrero, R., Hildesheim, A., Sherman, M. E., Bratti, M., Wacholder, S., Alfaro, M., Hutchinson, M., Morales, J., Greenberg, M. D., et al. (2000) · JAMA · doi:10.1001/jama.283.1.87 · Cited by 540
Cited by
Ronco, G., Dillner, J., Elfström, K. M., Tunesi, S., Snijders, P. J. F., Arbyn, M., Kitchener, H., Segnan, N., Gilham, C., Giorgi-Rossi, P., et al. (2014) · The Lancet · doi:10.1016/s0140-6736(13)62218-7 · Cited by 1,810
Self-citationScreening for Cervical Cancer: US Preventive Services Task Force Recommendation Statement
US Preventive Services Task Force, Curry, S. J., Krist, A. H., Owens, D. K., Barry, M. J., Caughey, A. B., Davidson, K. W., Doubeni, C. A., Epling, J. W., Kemper, A. R., et al. (2018) · JAMA · doi:10.1001/jama.2018.10897 · Cited by 1,409
Ronco, G., Giorgi-Rossi, P., Carozzi, F., Confortini, M., Palma, P. D., Del Mistro, A., Ghiringhello, B., Girlando, S., Gillio-Tos, A., De Marco, L., et al. (2010) · The Lancet Oncology · doi:10.1016/s1470-2045(09)70360-2 · Cited by 936
Self-citationEvidence Regarding Human Papillomavirus Testing in Secondary Prevention of Cervical Cancer
Arbyn, M., Ronco, G., Anttila, A., Meijer, C. J. L. M., Poljak, M., Ogilvie, G., Koliopoulos, G., Naucler, P., Sankaranarayanan, R., & Peto, J. (2012) · Vaccine · doi:10.1016/j.vaccine.2012.06.095 · Cited by 897
Self-citationMeijer, C. J. L. M., Berkhof, J., Castle, P. E., Hesselink, A. T., Franco, E. L., Ronco, G., Arbyn, M., Bosch, F. X., Cuzick, J., Dillner, J., et al. (2009) · International Journal of Cancer · doi:10.1002/ijc.24010 · Cited by 692
Self-citation
Metadata
- Authors
- Ronco, G., Giorgi-Rossi, P., Carozzi, F., Confortini, M., Palma, P. D., Del Mistro, A., Gillio-Tos, A., Minucci, D., Naldoni, C., Rizzolo, R., Schincaglia, P., Volante, R., Zappa, M., Zorzi, M., Cuzick, J., Segnan, N., & On behalf of the New Technologies for Cervical Cancer Screening Working Group
- Venue
- JNCI Journal of the National Cancer Institute
- Publisher
- Oxford University Press (OUP)
- Published
- 2008-03-25
- Volume
- 100
- Issue
- 7
- Pages
- 492-501
- ISSN
- 0027-8874 (ISSN-L)
- 1460-2105
- OpenAlex
- W2116458357
- Cited by
- 306
- References
- 33
- FWCI
- 24.31
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Results at Recruitment From a Randomized Controlled Trial Comparing Human Papillomavirus Testing Alone With Conventional Cytology as the Primary Cervical Cancer Screening Test. https://app.cochat.ai/papers/10.1093/jnci/djn065
- The paper
- Ronco, G., Giorgi-Rossi, P., Carozzi, F., Confortini, M., Palma, P. D., Del Mistro, A., Gillio-Tos, A., Minucci, D., Naldoni, C., Rizzolo, R., Schincaglia, P., Volante, R., Zappa, M., Zorzi, M., Cuzick, J., Segnan, N., & On behalf of the New Technologies for Cervical Cancer Screening Working Group. (2008). Results at Recruitment From a Randomized Controlled Trial Comparing Human Papillomavirus Testing Alone With Conventional Cytology as the Primary Cervical Cancer Screening Test. JNCI Journal of the National Cancer Institute. https://doi.org/10.1093/jnci/djn065
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.